FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 776 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... September 1, 2022 Flame of Hope Awards: Celebrating our volunteers April 3, 2023 Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer May 4, 2022 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... Oncotype DX Breast Cancer Test May Be Less Accurate for Black... Get the Facts Before Using Online Information News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and...
